IsoStent starts US trial of radioactive stent
This article was originally published in Clinica
IsoStent has started US trials of its radioactive Palmaz-Schatz stent. The company hopes that low level radiation will prevent excessive arterial wall remodelling, an unavoidable reaction to the presence of metallic implants on the vessel wall. IRIS, the IsoStent for Restenosis Intervention Study, will follow 30 patients at three US hospitals, but the stents will be made in Germany at the Karlsruhe Research Centre's cyclotron facility.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.